New Zealand Gazette – 2016 – No. 40

Page 67

✨ Trade Name Product Registration Notices



NEW ZEALAND GAZETTE, No. 40 — 5 MAY 2016

Under sections 16 and 17 of the Act, a written submission:

  1. must state in full the reasons for making the submission; and
  2. may state any decision sought on that application; and
  3. must be received by the director-general no later than 30 working days after the date of notification in the
    New Zealand Gazette.

Under section 18 of the Act, a copy of every submission will be forwarded to the applicant for the applicant’s
information.

The following address is:

  1. where submissions on this application are to be sent; and
  2. where requests for copies of the public information relating to the application can be sent; and
  3. where public information relating to the application can be viewed; and
  4. the director-general’s address for service:

ACVM Group, Ministry for Primary Industries, Pastoral House, 25 The Terrace, Wellington 6011. Postal
Address: PO Box 2526, Wellington 6140.

The applicant’s address for service is:

Biomin New Zealand Limited, The Corner, 9 Remuera Road, Newmarket, Auckland 1050. Postal Address:
PO Box 9707, Auckland 1149.

Dated at Wellington this 2nd day of May 2016.

MAREE ZINZLEY, Manager Approvals Operations, Ministry for Primary Industries (acting under delegated
authority).

2016-go2537

Notice of Application to Register a Trade Name Product (Notice No. MPI 625)

Maree Zinzley, Manager Approvals Operations of the Ministry for Primary Industries (MPI), acting under
delegated authority from the Director-General of MPI, gives notice, under section 14(1) of the Agricultural
Compounds and Veterinary Medicines Act 1997 (“Act”), that the following application has been made to register a
trade name product under section 9(1) of the Act:

Trade Name: Mastiplan

Reference: A11329

Active Ingredients and Concentrations:

  • Cefapirin (as sodium salt) 300mg and prednisolone 20mg

Formulation Type: Cerate

General Use Claim:

  • Broad spectrum treatment of clinical mastitis in lactating cows caused by Gram positive bacteria and Gram
    negative bacteria sensitive to cefapirin.
  • Treatment of subclinical mastitis and reduction in somatic cell count during lactation.
  • Reduction in local signs of inflammation and fever induced by clinical mastitis and rapid recovery in milk
    production.

Any person may make a written submission to the director-general concerning this application.

Under sections 16 and 17 of the Act, a written submission:

  1. must state in full the reasons for making the submission; and
  2. may state any decision sought on that application; and
  3. must be received by the director-general no later than 30 working days after the date of notification in the
    New Zealand Gazette.

Under section 18 of the Act, a copy of every submission will be forwarded to the applicant for the applicant’s
information.

The following address is:

67



Next Page →



Online Sources for this page:

Gazette.govt.nz — PDF NZ Gazette 2016, No 40




✨ LLM interpretation of page content

🌾 Notice of Application to Register a Trade Name Product (Notice No. MPI 624)

🌾 Primary Industries & Resources
2 May 2016
Trade Name Registration, Agricultural Compounds, Veterinary Medicines, MPI
  • Maree Zinzley, Manager Approvals Operations, Ministry for Primary Industries

🌾 Notice of Application to Register a Trade Name Product (Notice No. MPI 625)

🌾 Primary Industries & Resources
2 May 2016
Trade Name Registration, Agricultural Compounds, Veterinary Medicines, MPI, Mastiplan
  • Maree Zinzley, Manager Approvals Operations, Ministry for Primary Industries